# Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)

> **NCT06770855** · NA · NOT_YET_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 23 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **PROCEDURE:** Total consolidative MPDT

## Key facts

- **NCT ID:** NCT06770855
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-11
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770855, "Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06770855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*